$KALA News

Kala Bio Q1 EPS $(0.14) Beats $(0.30) Estimate

Kala Bio Announces 1-For-50 Reverse Stock Split, Effective May 11

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Kala Bio Q4 EPS $0.86 Beats $(1.44) Estimate, Sales $0.00

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Kala Bio Highlights Launch Of Agentic AI Platform

EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch

Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

Kala Bio shares are trading higher after the company announced that its first commercial healthcare AI product will be ready to ship in approximately 14 days.

Kala Bio shares are trading higher after the company announced that its first commercial healthcare AI product will be ready to ship in approximately 14 days.

Kala Bio Chases 'Palantir For Biotech' Dream With New AI Platform

Kala Bio Said It Is Ready To Ship Its First Commercial AI Product In Approximately 14 Days, As It Targets The $180+ Billion AI-In-Healthcare Market

Stock Trend Capital Provides Younet AI Investment Update

KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

KALA BIO Announces Strategic Initiative To Build On-Premises AI Infrastructure Platform To Be Deployed Directly Within Biotech And Pharmaceutical Client Environments

Kala Bio CFO, CEO David Lazar Resigns, Avi Minkowitz Appointed Successor